CD105 Antagonist Sensitization of Prostate Cancer to Radiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as radiation and androgen-targeted therapies, often face resistance from prostate cancer cells, particularly those with neuroendocrine differentiation, where CD105-expressing fibroblasts play a crucial role in tumor progression and resistance, necessitating a method to sensitize these cancers to existing therapies.
Innovation Solution
Administering a CD105 antagonist, like TRC105, in combination with cancer therapies to target CD105-expressing fibroblasts, thereby sensitizing prostate cancer cells to radiation and hormone therapies, and reducing tumor growth and recurrence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies (radiation, androgen-targeted therapy) are used, then treatment is provided, but cancer cells develop resistance particularly those with neuroendocrine differentiation
Solution Approach 1:
The patent segments the cancer microenvironment into distinct cellular components, specifically targeting CD105-expressing fibroblasts as a separate therapeutic target from the cancer cells themselves. This segmentation allows for selective intervention in the fibroblast-mediated resistance mechanism without directly affecting cancer cell therapy responses.
Solution Approach 2:
The patent identifies CD105-expressing fibroblasts as intermediary cells that mediate between the tumor microenvironment and cancer cell therapy resistance. By targeting this intermediary population with CD105 antagonists, the invention disrupts the protective signaling pathway that fibroblasts create for neuroendocrine-differentiated cancer cells.
2Quantity of substance
If CD105 antagonist is administered alone, then tumor vascularity is reduced, but additional therapy combination is needed for complete sensitization
Solution Approach 1:
The patent merges the anti-vascular effect of CD105 antagonists with conventional cancer therapies (radiation, chemotherapy, androgen-targeted therapy) into a combined treatment regimen. This combination approach integrates the vascularity-reducing effect with direct anti-cancer mechanisms to achieve synergistic tumor sensitization.
Solution Approach 2:
The patent changes the physiological parameters of the tumor microenvironment by reducing vascularity through CD105 antagonism. This parameter change (decreased vascularity) creates a less protective microenvironment that enhances the effectiveness of subsequent cancer therapies.
3Reliability
If cancer therapies are intensified to overcome resistance, then treatment efficacy may improve, but side effects and toxicity increase
Solution Approach 1:
By targeting CD105-expressing fibroblasts as an intermediary population, the patent reduces therapy toxicity by interfering with the protective microenvironment rather than directly increasing cancer cell kill. This indirect approach sensitizes tumors to standard doses of conventional therapies without requiring toxic intensification.
Solution Approach 2:
The patent substitutes the mechanical approach of intensifying cancer therapy doses with a biochemical approach of modifying the microenvironment through CD105 antagonism. This substitution achieves sensitization through molecular intervention rather than physical dose escalation, thereby reducing toxicity.
Data Source
AI summary
Described herein is a method of sensitizing a cancer in a subject and methods of treating, slowing the progression of, reducing the severity of, preventing the recurrence of, and/or reducing the recurrence likelihood of a cancer in a subject. The invention further provides for a method of preventing the recurrence of and/or reducing the recurrence likelihood of a cancer in a subject who has been treated with a cancer therapy.